Vadastuximab is a novel antibody-drug conjugate representing a significant advancement in the management of acute myeloid leukemia (AML). This groundbreaking therapy specifically targets CD33, a protein https://bookmarklinking.com/story11023590/vadastuximab-a-deep-dive-into-cd33-targeted-therapy